Equity Overview
Price & Market Data
Price: $0.0193
Daily Change: -$0.0027 / 13.99%
Range: $0.0156 - $0.0216
Market Cap: $806,807
Volume: 27,474
Performance Metrics
1 Week: -21.83%
1 Month: -32.75%
3 Months: -90.25%
6 Months: -93.61%
1 Year: -98.23%
YTD: -90.73%
Company Details
Employees: 40
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.